Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Amatuximab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Amatuximab?

Amatuximab is an investigational drug.

There have been 4 clinical trials for Amatuximab. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2008.

The most common disease conditions in clinical trials are Mesothelioma, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are Morphotek, National Cancer Institute (NCI), and [disabled in preview].

Recent Clinical Trials for Amatuximab
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).MorphotekPhase 2
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing CancersMorphotekPhase 1
Amatuximab for High Mesothelin CancersNational Cancer Institute (NCI)Phase 0

See all Amatuximab clinical trials

Clinical Trial Summary for Amatuximab

Top disease conditions for Amatuximab
Top clinical trial sponsors for Amatuximab

See all Amatuximab clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.